Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVE: Inhaled tranexamic acid or terlipressin for emergency treatment of hemoptysis
2020-005931-58Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in hemoptysis comparing Inhaled tranexamic acid, Inhaled terlipressin and Placebo (normal saline) (3 arms). Primary endpoint: Primary endpoint: resolution of hemoptysis without interventional procedure. Started Feb 2021; status: active.
02
Drugs
tranexamic acidterlipressin
03
Conditions
hemoptysis
Beyond the preview
Go deeper on 2020-005931-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005931-58.